nodes	percent_of_prediction	percent_of_DWPC	metapath
Salmeterol—ADRB2—Adrenoceptors—ADRA2C—attention deficit hyperactivity disorder	0.121	0.121	CbGpPWpGaD
Salmeterol—ADRB2—Adrenoceptors—ADRA2A—attention deficit hyperactivity disorder	0.0636	0.0636	CbGpPWpGaD
Salmeterol—ADRB2—Monoamine GPCRs—ADRA2C—attention deficit hyperactivity disorder	0.0428	0.0428	CbGpPWpGaD
Salmeterol—ADRB2—Monoamine GPCRs—DRD5—attention deficit hyperactivity disorder	0.042	0.042	CbGpPWpGaD
Salmeterol—ADRB2—Amine ligand-binding receptors—ADRA2C—attention deficit hyperactivity disorder	0.036	0.036	CbGpPWpGaD
Salmeterol—ADRB2—Amine ligand-binding receptors—DRD5—attention deficit hyperactivity disorder	0.0353	0.0353	CbGpPWpGaD
Salmeterol—ADRB2—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.0254	0.0254	CbGpPWpGaD
Salmeterol—ADRB2—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.0244	0.0244	CbGpPWpGaD
Salmeterol—ADRB2—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.0236	0.0236	CbGpPWpGaD
Salmeterol—ADRB2—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.0229	0.0229	CbGpPWpGaD
Salmeterol—ADRB2—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.0225	0.0225	CbGpPWpGaD
Salmeterol—ADRB2—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.0222	0.0222	CbGpPWpGaD
Salmeterol—ADRB2—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.0214	0.0214	CbGpPWpGaD
Salmeterol—ADRB2—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.0207	0.0207	CbGpPWpGaD
Salmeterol—ADRB2—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.0199	0.0199	CbGpPWpGaD
Salmeterol—ADRB2—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.0192	0.0192	CbGpPWpGaD
Salmeterol—ADRB2—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.0189	0.0189	CbGpPWpGaD
Salmeterol—ADRB2—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.0187	0.0187	CbGpPWpGaD
Salmeterol—ADRB2—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.0174	0.0174	CbGpPWpGaD
Salmeterol—ADRB2—G alpha (s) signalling events—DRD5—attention deficit hyperactivity disorder	0.0146	0.0146	CbGpPWpGaD
Salmeterol—ADRB2—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.0145	0.0145	CbGpPWpGaD
Salmeterol—ADRB2—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.0122	0.0122	CbGpPWpGaD
Salmeterol—ADRB2—GPCRs, Other—DRD3—attention deficit hyperactivity disorder	0.0102	0.0102	CbGpPWpGaD
Salmeterol—ADRB2—GPCRs, Other—DRD4—attention deficit hyperactivity disorder	0.00987	0.00987	CbGpPWpGaD
Salmeterol—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00952	0.00952	CbGpPWpGaD
Salmeterol—CYP3A7—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00871	0.00871	CbGpPWpGaD
Salmeterol—ADRB2—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00827	0.00827	CbGpPWpGaD
Salmeterol—ADRB2—G alpha (s) signalling events—DRD1—attention deficit hyperactivity disorder	0.0082	0.0082	CbGpPWpGaD
Salmeterol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.0081	0.0081	CbGpPWpGaD
Salmeterol—ADRB2—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.0081	0.0081	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00804	0.00804	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00708	0.00708	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00694	0.00694	CbGpPWpGaD
Salmeterol—ADRB2—GPCRs, Other—HTR2A—attention deficit hyperactivity disorder	0.00644	0.00644	CbGpPWpGaD
Salmeterol—CYP3A5—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00629	0.00629	CbGpPWpGaD
Salmeterol—ADRB2—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00561	0.00561	CbGpPWpGaD
Salmeterol—CYP2C8—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00545	0.00545	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00539	0.00539	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00528	0.00528	CbGpPWpGaD
Salmeterol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00491	0.00491	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00481	0.00481	CbGpPWpGaD
Salmeterol—CYP3A7—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00466	0.00466	CbGpPWpGaD
Salmeterol—CYP3A7—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00463	0.00463	CbGpPWpGaD
Salmeterol—CYP3A7—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00459	0.00459	CbGpPWpGaD
Salmeterol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00456	0.00456	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00454	0.00454	CbGpPWpGaD
Salmeterol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00442	0.00442	CbGpPWpGaD
Salmeterol—ADRB2—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00434	0.00434	CbGpPWpGaD
Salmeterol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00429	0.00429	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.0042	0.0042	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00413	0.00413	CbGpPWpGaD
Salmeterol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00399	0.00399	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00391	0.00391	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00378	0.00378	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00372	0.00372	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00367	0.00367	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00366	0.00366	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00342	0.00342	CbGpPWpGaD
Salmeterol—CYP3A5—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00337	0.00337	CbGpPWpGaD
Salmeterol—CYP3A5—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00334	0.00334	CbGpPWpGaD
Salmeterol—CYP3A5—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00332	0.00332	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.0032	0.0032	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00305	0.00305	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00299	0.00299	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00298	0.00298	CbGpPWpGaD
Salmeterol—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00293	0.00293	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00292	0.00292	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.0029	0.0029	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00288	0.00288	CbGpPWpGaD
Salmeterol—CYP2C8—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00288	0.00288	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00283	0.00283	CbGpPWpGaD
Salmeterol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.0028	0.0028	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.0028	0.0028	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00277	0.00277	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00271	0.00271	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00261	0.00261	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00244	0.00244	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.0024	0.0024	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00207	0.00207	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.0019	0.0019	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.0019	0.0019	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00188	0.00188	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00183	0.00183	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00181	0.00181	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00168	0.00168	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00164	0.00164	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00163	0.00163	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00163	0.00163	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.0016	0.0016	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.0016	0.0016	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00158	0.00158	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00157	0.00157	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00157	0.00157	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00155	0.00155	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00154	0.00154	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00153	0.00153	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00148	0.00148	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00147	0.00147	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00145	0.00145	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00144	0.00144	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00138	0.00138	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00134	0.00134	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00131	0.00131	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00131	0.00131	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00129	0.00129	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.0012	0.0012	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00119	0.00119	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00111	0.00111	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.00105	0.00105	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.00103	0.00103	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.001	0.001	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00097	0.00097	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00095	0.00095	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00095	0.00095	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000937	0.000937	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000935	0.000935	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000902	0.000902	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000874	0.000874	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000869	0.000869	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000859	0.000859	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000848	0.000848	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000823	0.000823	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000823	0.000823	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00081	0.00081	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—COMT—attention deficit hyperactivity disorder	0.000797	0.000797	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000791	0.000791	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00079	0.00079	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.00076	0.00076	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000753	0.000753	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000723	0.000723	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000658	0.000658	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00064	0.00064	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000626	0.000626	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—COMT—attention deficit hyperactivity disorder	0.000576	0.000576	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000572	0.000572	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000553	0.000553	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—COMT—attention deficit hyperactivity disorder	0.000499	0.000499	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000495	0.000495	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.00048	0.00048	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000442	0.000442	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000442	0.000442	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000435	0.000435	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000404	0.000404	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000353	0.000353	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—EP300—attention deficit hyperactivity disorder	0.000342	0.000342	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000336	0.000336	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000293	0.000293	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	0.000268	0.000268	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000266	0.000266	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—EP300—attention deficit hyperactivity disorder	0.000247	0.000247	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—EP300—attention deficit hyperactivity disorder	0.000214	0.000214	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	0.000115	0.000115	CbGpPWpGaD
